3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
114
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Recurrence
17
Burkitt Lymphoma
14
Lymphoma, Large B-Cell, Diffuse
8
Neoplasms
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
6
Neoplasms, Plasma Cell
6
Lymphoma
6
Leukemia, Biphenotypic, Acute
5
Immunoglobulin Light-chain Amyloidosis
5
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Lymphoma, B-Cell
4
Waldenstrom Macroglobulinemia
3
Neoplasm Metastasis
3
Nausea
3
Lung Neoplasms
3
Leukemia
3
Smoldering Multiple Myeloma
2
Rectal Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Paraproteinemias
2
Ovarian Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Down Syndrome
2
Interventions
Etoposide
3
daratumumab
2
Vincristine
2
Prednisone
2
Doxorubicin
2
Cyclophosphamide
2
varlilumab
1
prednylidene
1
pomalidomide
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
Specimen Handling
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Disulfides
1
Dexamethasone
1
Cytarabine
1
Carmustine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmablastic Lymphoma
×
Dexamethasone
×
90 days
×
Clear all
NCT04915248
2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled